What did @peptideparty actually say?
The creator described having an anxiety attack, dosing what appears to be selank (a peptide associated with anxiolytic effects) at 1mg subcutaneously, and experiencing relief within "about 15, 20 minutes." They also connected this to ADHD-related anxiety and contrasted it with stimulant medications that, in their experience, cause a crash. The claim, stated plainly: one subcutaneous dose resolved an active anxiety attack the same day.
They also noted prior failures with nasal administration and smaller doses, suggesting the dose and route mattered. That detail is actually worth paying attention to, because bioavailability differences between intranasal and subcutaneous delivery are real and documented.
Does the science back this up?
Partially, but with major asterisks. Selank is a synthetic heptapeptide derived from tuftsin, developed in Russia by the Institute of Molecular Genetics. Animal studies and a limited number of Russian clinical trials have shown anxiolytic effects, primarily through modulation of GABAergic transmission and influence on brain-derived neurotrophic factor (BDNF). Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) found selank reduced anxiety behaviors in rodent models without sedation. A small human trial by Zozulya et al. (2001, Bulletin of Experimental Biology and Medicine) reported reduced anxiety in patients with generalized anxiety disorder compared to medazepam.
Here is the problem: those trials are small, largely conducted in Russia, not replicated in large Western randomized controlled trials, and not reviewed by the FDA for any indication. The 15-to-20-minute onset the creator describes is plausible pharmacologically for a subcutaneous peptide with CNS activity, but "plausible" is not the same as "proven." Anecdote is not a clinical trial.
What did they get wrong (or right)?
They got the stimulant crash observation basically right. It is a well-documented limitation of short-acting ADHD medications. The "crash" phenomenon reflects the half-life of agents like amphetamine salts, and anxiety rebound is a recognized side effect (Faraone et al., 2005, CNS Drugs). That part of their framing is fair.
What they got wrong, or at least oversimplified: attributing a single dose's effect to the peptide with certainty. Anxiety attacks are self-limiting by nature. Most panic and anxiety episodes resolve within 20 to 60 minutes regardless of intervention, a fact called the natural course of a panic attack (Craske and Barlow, 1988, Journal of Abnormal Psychology). The creator has no way to know whether selank resolved the anxiety or whether the anxiety would have resolved anyway. This is not a small caveat. It is the entire methodological problem.
They also said "1MG" as though that dose is self-evidently correct. We are not going to validate that framing. Dose guidance for unapproved compounds requires clinical oversight, full stop.
What should you actually know?
Selank is not FDA-approved for any condition. It is not legal to market it as a treatment for anxiety, ADHD, or anything else in the United States. Compounded versions exist in a regulatory gray zone, and quality control across suppliers varies significantly. The peptide has a genuinely interesting mechanism and some early evidence worth watching, but "worth watching" is not the same as "use this during an anxiety attack."
If you have ADHD and anxiety, that combination is extremely common and extremely treatable through evidence-based pathways. Non-stimulant options like atomoxetine, viloxazine, and guanfacine have actual clinical trial data behind them. Cognitive behavioral therapy has decades of randomized evidence. None of that is as exciting as a peptide story on TikTok, but the evidence base is real.
Self-treating an active mental health episode with an unregulated compound purchased outside a clinical relationship is not a strategy we can endorse, regardless of how compelling one person's afternoon felt.
Bottom line
The creator's experience sounds genuine, and selank has more research behind it than most peptides being discussed on TikTok. But one person's anxiety attack resolving after a subcutaneous injection tells us almost nothing about whether selank caused that resolution. The science is preliminary. The regulatory status is unsettled. And the method, self-dosing an unapproved compound during an acute mental health episode, carries risks that a 14-second relief story cannot fully capture.